Perceptive Advisors LLC increased its stake in Athenex Inc (NASDAQ:ATNX) by 77.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,096,022 shares of the company’s stock after purchasing an additional 2,226,494 shares during the quarter. Athenex comprises about 1.2% of Perceptive Advisors LLC’s portfolio, making the stock its 24th biggest holding. Perceptive Advisors LLC owned 0.08% of Athenex worth $32,550,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently bought and sold shares of ATNX. Vanguard Group Inc lifted its holdings in Athenex by 8.3% in the third quarter. Vanguard Group Inc now owns 1,878,063 shares of the company’s stock worth $29,185,000 after purchasing an additional 144,410 shares during the period. Vanguard Group Inc. raised its position in Athenex by 8.3% in the third quarter. Vanguard Group Inc. now owns 1,878,063 shares of the company’s stock worth $29,185,000 after acquiring an additional 144,410 shares in the last quarter. American Century Companies Inc. bought a new stake in Athenex in the third quarter worth about $1,894,000. BlackRock Inc. raised its position in Athenex by 3.2% in the third quarter. BlackRock Inc. now owns 3,582,578 shares of the company’s stock worth $55,673,000 after acquiring an additional 110,332 shares in the last quarter. Finally, Citigroup Inc. raised its position in Athenex by 146.8% in the fourth quarter. Citigroup Inc. now owns 129,927 shares of the company’s stock worth $1,649,000 after acquiring an additional 77,284 shares in the last quarter. 31.75% of the stock is owned by institutional investors and hedge funds.
Shares of Athenex stock opened at $12.40 on Tuesday. The company has a current ratio of 3.31, a quick ratio of 2.75 and a debt-to-equity ratio of 0.36. Athenex Inc has a 52 week low of $9.83 and a 52 week high of $20.90. The stock has a market capitalization of $795.57 million, a price-to-earnings ratio of -8.61 and a beta of 0.23.
Athenex (NASDAQ:ATNX) last issued its quarterly earnings results on Monday, March 11th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.21). Athenex had a negative return on equity of 66.23% and a negative net margin of 131.81%. The business had revenue of $21.27 million during the quarter. As a group, analysts predict that Athenex Inc will post -1.66 earnings per share for the current year.
Several equities research analysts have commented on the stock. BidaskClub cut shares of Athenex from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Royal Bank of Canada reiterated an “outperform” rating on shares of Athenex in a research report on Tuesday, March 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. Athenex has a consensus rating of “Hold” and a consensus target price of $20.00.
In related news, CEO Johnson Yiu Nam Lau acquired 10,000 shares of the business’s stock in a transaction on Monday, March 11th. The shares were purchased at an average price of $11.78 per share, for a total transaction of $117,800.00. Following the acquisition, the chief executive officer now owns 2,917,422 shares in the company, valued at $34,367,231.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Sheldon Trainor-Degirolamo sold 45,915 shares of the business’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $11.77, for a total value of $540,419.55. Following the sale, the director now owns 4,000 shares in the company, valued at approximately $47,080. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 26,000 shares of company stock worth $309,120 and sold 132,240 shares worth $1,559,044. 29.50% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Athenex Inc (ATNX) Shares Bought by Perceptive Advisors LLC” was published by Highlight Press and is the property of of Highlight Press. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://highlightpress.com/2019/03/19/athenex-inc-atnx-shares-bought-by-perceptive-advisors-llc.html.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
Read More: Is the QQQ ETF safe?
Want to see what other hedge funds are holding ATNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athenex Inc (NASDAQ:ATNX).
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.